Results 291 to 300 of about 333,854 (331)

Preoperative Activation of c-Src Kinase in Atrial Tissue in Patients Developing Postoperative Atrial Fibrillation. [PDF]

Medicina (Kaunas)
Bonda TA, Dziemidowicz M, Hirnle T, Dmitruk I, Bialuk I, Winnicka MM.   +5 more
europepmc   +1 more source

A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer. [PDF]

Front Oncol
Rangarajan A, Sviezhentseva I, Gunderson E, Pikman Y, Jacobson MP, Apsel Winger B.   +5 more
europepmc   +1 more source

Molecular Mechanisms and Treatment Strategies of ALK-Positive Lung Cancer: A Beginner's Guide for Patients, Their Families and Carers. [PDF]

Thorac Cancer
Klenova E.
europepmc   +1 more source

Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer. [PDF]

Cancer Drug Resist
Xu G, Pecoraro C, Vahabi M, Deng D, Cavazzoni A, Fiuji H, Lagrasta CAM, Cascioferro SM, Tiseo M, Carbone D, Avan A, Zucali PA, Assaraf YG, Peters GJ, Diana P, Giovannetti E.   +15 more
europepmc   +1 more source

Counter-Therapeutic Strategies for Resistance of FLT3 Inhibitors in Acute Myeloid Leukemia. [PDF]

Cells
Song MK.
europepmc   +1 more source

[Animal protein tyrosine kinases].

Postepy biochemii, 2002
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Protein tyrosine kinases and cancer

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1997
4. Tyrosine kinase activation by mutation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F222 4.1. BCR–ABL and human leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F222 4.2. TEL–ABL and human leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F224 4.3.
K S, Kolibaba, B J, Druker
openaire   +2 more sources

Inhibitors of protein tyrosine kinases

Current Opinion in Biotechnology, 1995
The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire   +2 more sources